Market Overview

UPDATE: Piper Jaffray Reduces PT to $92 on Monsanto on Pipeline Valuation

Share:
Related MON
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
Materials Mavens: Sector ETFs To Embrace
Monsanto Acquisition Has Driven Bayer Deep Into Value Territory (Seeking Alpha)

Piper Jaffray reiterates its Overweight rating on Monsanto (NYSE: MON) but reduces its price target on shares from $97 to $92 on compassed valuation multiples.

Piper Jaffray comments, "As valuation multiples have compressed in the agriculture sector (as well as large cap biotech – a commonly used peer group for MON shares), scrutiny around the sustainability of MON's premium multiple has intensified. In this note, we revisit our Overweight thesis on MON shares and outline how Monsanto is positioned to deliver at least mid-teens annual earnings growth over the next 3 years, which should be supportive of sustained P/E valuations. Latin America will continue to be a key profit growth driver over the next 2 years - a factor that we believe investors under-estimate. Following a review of Monsanto's R&D pipeline, we provide a framework to value this pipeline – which we believe is worth approximately $13 per share."

MON closed at $71.30 on Tuesday.

Latest Ratings for MON

DateFirmActionFromTo
Nov 2016OTR GlobalUpgradesNegativeMixed
Oct 2016BarclaysMaintainsEqual-weight
Sep 2016Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for MON
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (MON)

View Comments and Join the Discussion!